PMID- 16761999
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20111117
IS  - 1478-3223 (Print)
IS  - 1478-3223 (Linking)
VI  - 26
IP  - 5
DP  - 2006 Jun
TI  - Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American 
      patients outside DR3 and DR4.
PG  - 552-8
AB  - AIMS: To determine the clinical phenotype and outcome of patients with definite 
      type 1 autoimmune hepatitis, who lack human leukocyte antigen (HLA) DR3 and DR4, 
      and to assess the importance of HLA DR7 and DR13. METHODS: Two hundred and seven 
      adult patients were typed for DR3, DR4, DR7, and DR13 by DNA-based techniques. 
      One hundred and two blood donors constituted a normal population. RESULTS: 
      Twenty-six patients lacked DR3 and DR4 (13%). Treatment failure occurred more 
      commonly in these individuals than in the 68 patients with DR4 (20% vs. 3%, P = 
      0.03), and relapse after drug withdrawal was less frequent than in the 84 
      patients with DR3 (55% vs. 87%, P = 0.03). HLA DR13 occurred more often than in 
      those with DR3 (54% vs. 15%, P = 0.0002) or DR4 (54% vs. 12%, P = 0.00005), and 
      it was more frequent than in normal adults (54% vs. 22%, P = 0.003), including 
      those without DR3 or DR4 (54% vs. 27%, P = 0.03). HLA DR7 was not associated with 
      susceptibility or outcome. CONCLUSIONS: White North American patients who lack 
      DR3 and DR4 respond differently to corticosteroid treatment than patients with 
      classical HLA phenotypes. HLA DR13 is common in these adult patients, and it may 
      affect treatment outcome.
FAU - Czaja, Albert J
AU  - Czaja AJ
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 
      Rochester, MN 55905, USA. czaja.albert@mayo.edu
FAU - Carpenter, Herschel A
AU  - Carpenter HA
FAU - Moore, S Breanndan
AU  - Moore SB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR3 Antigen)
RN  - 0 (HLA-DR4 Antigen)
RN  - 0 (HLA-DR7 Antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*13:01 antigen)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Disease Susceptibility
MH  - Female
MH  - HLA Antigens/analysis
MH  - HLA-DR Antigens/*analysis
MH  - HLA-DR3 Antigen
MH  - HLA-DR4 Antigen
MH  - HLA-DR7 Antigen
MH  - HLA-DRB1 Chains
MH  - Hepatitis, Autoimmune/drug therapy/epidemiology/*immunology
MH  - Humans
MH  - Immunophenotyping
MH  - Male
MH  - Middle Aged
MH  - North America/epidemiology
MH  - Recurrence
MH  - Treatment Failure
MH  - Treatment Outcome
EDAT- 2006/06/10 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/06/10 09:00
PHST- 2006/06/10 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/06/10 09:00 [entrez]
AID - LIV1249 [pii]
AID - 10.1111/j.1478-3231.2006.01249.x [doi]
PST - ppublish
SO  - Liver Int. 2006 Jun;26(5):552-8. doi: 10.1111/j.1478-3231.2006.01249.x.